Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 3/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.38 |
| ▸ | DPEP1 | P16444 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8152875 | 0.87 | KDM4E (0.39) | PAX8RXFP1F2R | |
| SCHEMBL8160590 | 0.87 | KDM4E (0.39) | PAX8RXFP1F2R | |
| SCHEMBL27404045 | 0.71 | HTR2C (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2861143 | 0.69 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21820688 | 0.69 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2493402 | 0.69 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3587894 | 0.69 | TACR1 (0.44) | — | |
| SCHEMBL4493249 | 0.69 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2712838 | 0.69 | TACR1 (0.44) | — | |
| SCHEMBL2712836 | 0.69 | TACR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420622-B2 | Silylated piperidine derivatives | Merck, Sharp & Dohme, Corp. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2120584-B1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-2120584-A1 | SILYLATED PIPERIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008085301-A1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | PSEN1, PSEN2, SRM | PAX8 4843/4885PSEN1 1/4885PSEN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.